Back

Genetically engineered microglia-like cells have therapeutic potential for neurodegenerative disease

Plasschaert, R. N.; DeAndrade, M. P.; Hull, F.; Nguyen, Q.; Peterson, T.; Yan, A.; Loperfido, M.; Baricordi, C.; Barbarossa, L.; Yoon, J. K.; Dogan, Y.; Unnisa, Z.; Schindler, J. W.; van Til, N. P.; Biasco, L.; Mason, C.

2021-09-18 neuroscience
10.1101/2021.09.16.460703 bioRxiv
Show abstract

Hematopoietic stem/progenitor cell gene therapy (HSPC-GT) results in the engraftment of genetically modified microglia-like cells (MLCs) in the brain. While HSPC-GT has shown a clear neurological benefit in the clinic for specific rare diseases, the nature of MLC engraftment in the brain and the functional characteristics of MLCs remain contentious. Here we comprehensively characterized how different routes of administration affect the engraftment and biodistribution of genetically engineered HSPC-derivatives in mice. Using high-throughput single-cell profiling, we show that MLCs bear a transcriptional signature similar to resident microglia rather than invading macrophages. However, MLCs could clearly be distinguished from resident microglia by expression of a specific set of genes. Finally, in murine models of Parkinsons disease and frontotemporal dementia, we demonstrate that MLCs can provide therapeutically relevant levels of protein to the brain, thereby potentially opening avenues of HSPC-GT to address the underlying disease etiology of these and other similar disorders.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.